RESUMO Introdução: Lesão renal aguda (LRA) ocorre frequentemente em pacientes com COVID-19 e associa-se a maior morbidade e mortalidade. Conhecer riscos da LRA permite a identificação, prevenção e tratamento oportuno. Este estudo teve como objetivo identificar fatores de risco associados à LRA em pacientes hospitalizados. Métodos: Realizou-se estudo descritivo, retrospectivo, transversal e de componente analítico de pacientes adultos hospitalizados com COVID-19 de 1º de março a 31 de dezembro, 2020. Definiu-se a LRA pelos critérios de creatinina das diretrizes KDIGO-LRA. Informações sobre fatores de risco foram obtidas de prontuários eletrônicos. Resultados: Dos 934 pacientes, 42,93% desenvolveram LRA, 60,59% KDIGO-1 e 9,9% necessitaram de terapia renal substitutiva. Pacientes com LRA apresentaram maior tempo de internação, maior mortalidade e necessitaram de mais internações em UTIs, ventilação mecânica e suporte vasopressor. A análise multivariada mostrou que idade (OR 1,03; IC 95% 1,02–1,04), sexo masculino (OR 2,13; IC 95% 1,49–3,04), diabetes mellitus (DM) (OR 1,55; IC 95% 1,04–2,32), doença renal crônica (DRC) (OR 2,07; IC 95% 1,06–4,04), proteína C reativa (PCR) (OR 1,02; IC 95% 1,00–1,03), admissão em UTI (OR 1,81; IC 95% 1,04–3,16) e suporte vasopressor (OR 7,46; IC 95% 3,34–16,64) foram fatores de risco para LRA, e que bicarbonato (OR 0,89; IC 95% 0,84–0,94) e índice de pressão parcial de oxigênio arterial/fração inspirada de oxigênio (OR 0,99; IC 95% 0,98–0,99) poderiam ser fatores de proteção. Conclusões: Documentou-se alta frequência de LRA em pacientes com COVID-19, com diversos preditores: idade, sexo masculino, DM, DRC, PCR, admissão em UTI e suporte vasopressor. LRA ocorreu mais frequentemente em pacientes com maior gravidade da doença e associou-se a maior mortalidade e piores desfechos. Introdução (LRA COVID19 COVID 19 COVID-1 associase associa se identificação oportuno Métodos Realizouse Realizou descritivo retrospectivo º 3 dezembro 2020 Definiuse Definiu KDIGOLRA. KDIGOLRA KDIGO LRA. KDIGO-LRA eletrônicos Resultados 93 4293 42 42,93 6059 60 59 60,59 KDIGO1 1 KDIGO- 99 9 9,9 substitutiva internação UTIs OR 1,03 103 03 95 1,02–1,04, 102104 1,02–1,04 , 02 04 1,02–1,04) 2,13 213 2 13 1,49–3,04, 149304 1,49–3,04 49 1,49–3,04) DM (DM 1,55 155 55 1,04–2,32, 104232 1,04–2,32 32 1,04–2,32) DRC (DRC 2,07 207 07 1,06–4,04, 106404 1,06–4,04 06 4 1,06–4,04) PCR (PCR 1,02 102 1,00–1,03, 100103 1,00–1,03 00 1,00–1,03) 1,81 181 81 1,04–3,16 104316 16 7,46 746 7 46 3,34–16,64 3341664 34 64 0,89 089 0 89 0,84–0,94 084094 84 94 arterialfração arterial fração 0,99 099 0,98–0,99 098099 98 proteção Conclusões Documentouse Documentou COVID19, 19, preditores associouse associou desfechos COVID1 COVID- 202 429 42,9 605 6 5 60,5 9, 1,0 10 10210 1,02–1,0 2,1 21 14930 1,49–3,0 1,5 15 10423 1,04–2,3 2,0 20 10640 1,06–4,0 10010 1,00–1,0 1,8 18 8 1,04–3,1 10431 7,4 74 3,34–16,6 334166 0,8 08 0,84–0,9 08409 0,9 09 0,98–0,9 09809 42, 60, 1, 1021 1,02–1, 2, 1493 1,49–3, 1042 1,04–2, 1064 1,06–4, 1001 1,00–1, 1,04–3, 1043 7, 3,34–16, 33416 0, 0,84–0, 0840 0,98–0, 0980 1,02–1 149 1,49–3 104 1,04–2 106 1,06–4 100 1,00–1 1,04–3 3,34–16 3341 0,84–0 084 0,98–0 098 1,02– 14 1,49– 1,04– 1,06– 1,00– 3,34–1 334 0,84– 0,98– 1,49 1,04 1,06 1,00 3,34– 33 0,84 0,98 1,4 3,34 3,3 3,
Abstract Introduction: Acute kidney injury (AKI) occurs frequently in COVID-19 patients and is associated with greater morbidity and mortality. Knowing the risks of AKI allows for identification, prevention, and timely treatment. This study aimed to identify the risk factors associated with AKI in hospitalized patients. Methods: A descriptive, retrospective, cross-sectional, and analytical component study of adult patients hospitalized with COVID-19 from March 1 to December 31, 2020 was carried out. AKI was defined by the creatinine criteria of the KDIGO-AKI guidelines. Information, regarding risk factors, was obtained from electronic medical records. Results: Out of the 934 patients, 42.93% developed AKI, 60.59% KDIGO-1, and 9.9% required renal replacement therapy. Patients with AKI had longer hospital stay, higher mortality, and required more intensive care unit (ICU) admission, mechanical ventilation, and vasopressor support. Multivariate analysis showed that age (OR 1.03; 95% CI 1.02–1.04), male sex (OR 2.13; 95% CI 1.49–3.04), diabetes mellitus (DM) (OR 1.55; 95% CI 1.04–2.32), chronic kidney disease (CKD) (OR 2.07; 95% CI 1.06–4.04), C-reactive protein (CRP) (OR 1.02; 95% CI 1.00–1.03), ICU admission (OR 1.81; 95% CI 1.04–3.16), and vasopressor support (OR 7.46; 95% CI 3.34–16.64) were risk factors for AKI, and that bicarbonate (OR 0.89; 95% CI 0.84–0.94) and partial pressure arterial oxygen/inspired oxygen fraction index (OR 0.99; 95% CI 0.98–0.99) could be protective factors. Conclusions: A high frequency of AKI was documented in COVID-19 patients, with several predictors: age, male sex, DM, CKD, CRP, ICU admission, and vasopressor support. AKI occurred more frequently in patients with higher disease severity and was associated with higher mortality and worse outcomes. Introduction (AKI COVID19 COVID 19 COVID-1 identification prevention treatment Methods descriptive retrospective crosssectional, crosssectional cross sectional, sectional cross-sectional 31 202 out KDIGOAKI KDIGO guidelines Information records Results 93 4293 42 42.93 6059 60 59 60.59 KDIGO1, KDIGO1 1, KDIGO-1 99 9 9.9 therapy stay (ICU ventilation OR 1.03 103 03 95 1.02–1.04, 102104 1.02–1.04 , 02 04 1.02–1.04) 2.13 213 2 13 1.49–3.04, 149304 1.49–3.04 49 3 1.49–3.04) DM (DM 1.55 155 55 1.04–2.32, 104232 1.04–2.32 32 1.04–2.32) CKD (CKD 2.07 207 07 1.06–4.04, 106404 1.06–4.04 06 4 1.06–4.04) Creactive C reactive CRP (CRP 1.02 102 1.00–1.03, 100103 1.00–1.03 00 1.00–1.03) 1.81 181 81 1.04–3.16, 104316 1.04–3.16 16 1.04–3.16) 7.46 746 7 46 3.34–16.64 3341664 34 64 0.89 089 0 89 0.84–0.94 084094 84 94 oxygeninspired inspired 0.99 099 0.98–0.99 098099 98 Conclusions predictors outcomes COVID1 COVID- 20 429 42.9 605 6 5 60.5 KDIGO- 9. 1.0 10 10210 1.02–1.0 2.1 21 14930 1.49–3.0 1.5 15 10423 1.04–2.3 2.0 10640 1.06–4.0 10010 1.00–1.0 1.8 18 8 10431 1.04–3.1 7.4 74 3.34–16.6 334166 0.8 08 0.84–0.9 08409 0.9 09 0.98–0.9 09809 42. 60. 1. 1021 1.02–1. 2. 1493 1.49–3. 1042 1.04–2. 1064 1.06–4. 1001 1.00–1. 1043 1.04–3. 7. 3.34–16. 33416 0. 0.84–0. 0840 0.98–0. 0980 1.02–1 149 1.49–3 104 1.04–2 106 1.06–4 100 1.00–1 1.04–3 3.34–16 3341 0.84–0 084 0.98–0 098 1.02– 14 1.49– 1.04– 1.06– 1.00– 3.34–1 334 0.84– 0.98– 1.49 1.04 1.06 1.00 3.34– 33 0.84 0.98 1.4 3.34 3.3 3.